NanoViricides has entered into an agreement with BASi to conduct drug development studies for IND applications to the FDA for its nanoviricides drug candidates against various viral diseases.   BASi will conduct cGLP and non-GLP studies that are designed to assess overall safety in animals receiving multiple doses of FluCide. Specific safety pharmacology studies will also be conducted to assess the effects of FluCide on cardiovascular, respiratory and central nervous systems. These studies are r...